{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:12:44Z","timestamp":1760242364511,"version":"build-2065373602"},"reference-count":33,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T00:00:00Z","timestamp":1494547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>The purpose of this study was to evaluate prediction of prognosis after first-line radioimmunotherapy (RIT) of advanced follicular non-Hodgkin lymphoma (FL), by imaging with fluorine-18-fluorodeoxyglucose positron emission tomography with computed tomography (18F-FDG-PET\/CT) three months after induction treatment by Iodine-131-rituximab (131I-rituximab). Objective response was determined using the Deauville 5-point scale in 68 prospective clinical trial patients. Baseline 18F-FDG-PET\/CT studies were used to calculate total-metabolic-tumor-volume (TMTV). Non-imaging studies included the Follicular lymphoma international prognostic index (FLIPI) and absolute baseline monocyte and lymphocyte counts. Patients were monitored for over ten years (median follow-up 59 months), and no patient was lost to follow-up. Complete response (CR) of 88% predicted excellent prognosis with median time-to-next-treatment (TTNT) not yet reached. Those patients (12%) who failed to achieve CR (Deauville \u2264 3) on 18F-FDG-PET\/CT at three months had significantly poorer outcomes (p &lt; 0.0001) with a median TTNT of 41 months. Requirement for re-treatment was predicted by FLIPI and absolute baseline monocyte count but not lymphocyte count. The TTNT was accurately predicted by 18F-FDG-PET\/CT Deauville response at three months following first-line therapy of FL with RIT. Early response demonstrated by imaging does, therefore, foretell prognosis in the individual FL patients.<\/jats:p>","DOI":"10.3390\/diagnostics7020026","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T11:03:53Z","timestamp":1494587033000},"page":"26","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Imaging of Early Response to Predict Prognosis in the First-Line Management of Follicular Non-Hodgkin Lymphoma with Iodine-131-Rituximab Radioimmunotherapy"],"prefix":"10.3390","volume":"7","author":[{"given":"Murali","family":"Kesavan","sequence":"first","affiliation":[{"name":"Departments of Haematology and Nuclear Medicine, The University of Western Australia, School of Medicine, Crawley 6009, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Boucek","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Nuclear Medicine, The University of Western Australia, School of Medicine, Crawley 6009, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"MacDonald","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Nuclear Medicine, The University of Western Australia, School of Medicine, Crawley 6009, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"McQuillan","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Nuclear Medicine, The University of Western Australia, School of Medicine, Crawley 6009, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Turner","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Nuclear Medicine, The University of Western Australia, School of Medicine, Crawley 6009, Western Australia, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood-2015-11-632745","article-title":"Is watch and wait still acceptable for patients with low-grade follicular lymphoma?","volume":"127","author":"Armitage","year":"2016","journal-title":"Blood"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","article-title":"Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies","volume":"34","author":"Meignan","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2352-3026(14)70008-0","article-title":"Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: A pooled analysis of central scan review in three multicentre studies","volume":"1","author":"Trotman","year":"2014","journal-title":"Lancet Haematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S1470-2045(15)00169-2","article-title":"Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: A retrospective analysis of a prospective clinical trial and validation in a population-based registry","volume":"16","author":"Pastore","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood-2006-01-013367","article-title":"The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome","volume":"108","author":"Buske","year":"2006","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.13332","article-title":"Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: An analysis from the FOLL05 trial of the Fondazione Italiana Linfomi","volume":"169","author":"Marcheselli","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2011.35.0736","article-title":"Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: Analysis of PET-CT in a subset of PRIMA trial participants","volume":"29","author":"Trotman","year":"2011","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1200\/JCO.2012.43.0934","article-title":"Impact of 18F fluorodeoxyglucose positron emission tomography response evaluation in patients with high-tumor burden follicular lymphoma treated with immunochemotherapy: A prospective study from the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte and GOELAMS","volume":"30","author":"Dupuis","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.3109\/10428194.2014.949260","article-title":"Phase II study of first-line 131I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic 18F-fluorodeoxyglucose positron emission tomography","volume":"56","author":"McQuillan","year":"2015","journal-title":"Leuk. Lymph."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: A randomized study from the Groupe d\u2019Etude des Lymphomes Folliculaires. Groupe d\u2019Etude des Lymphomes de l\u2019Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1088\/0031-9155\/53\/16\/001","article-title":"Assessment of tumour response with 18F-fluorodeoxyglucose positron emission tomography using three-dimensional measures compared to SUVmax\u2014A phantom study","volume":"53","author":"Boucek","year":"2008","journal-title":"Phys. Med. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","article-title":"Absolute lymphocyte count predicts overall survival in follicular lymphomas","volume":"134","author":"Siddiqui","year":"2006","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1038\/sj.leu.2404819","article-title":"Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas","volume":"21","author":"Porrata","year":"2007","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12185-014-1576-0","article-title":"Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma","volume":"99","author":"Kumagai","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.leukres.2013.07.015","article-title":"Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"37","author":"Watanabe","year":"2013","journal-title":"Leuk. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11864-006-0036-3","article-title":"Follicular lymphoma international prognostic index","volume":"7","year":"2006","journal-title":"Curr. Treat Opt. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Roy","year":"2004","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: A new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3960\/jslrt.52.77","article-title":"Retrospective study of the utility of FLIPI\/FLIPI-2 for follicular lymphoma patients treated with R-CHOP","volume":"52","author":"Numata","year":"2012","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.rcl.2008.03.003","article-title":"New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma","volume":"46","author":"Cheson","year":"2008","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_24","unstructured":"Motulsky, H. (2014). Intuitive Biostatistics: A Nonmathematical Guide to Statistical Thinking, Oxford University Press. [3rd ed.]."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2015-11-624288","article-title":"Follicular lymphoma: Evolving therapeutic strategies","volume":"127","author":"Kahl","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2016.70.6150","article-title":"On the cutoff of baseline total metabolic tumor volume in high-tumor-burden follicular lymphoma","volume":"35","author":"Laffon","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1200\/JCO.2016.71.0459","article-title":"Reply to H.J.A. Adams et al and E. Laffon et al","volume":"35","author":"Meignan","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_28","first-page":"928","article-title":"Response assessment criteria and their applications in lymphoma: Part 1","volume":"57","author":"Moghbel","year":"2016","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_29","first-page":"13","article-title":"Response assessment criteria and their applications in lymphoma: Part 2","volume":"58","author":"Moghbel","year":"2017","journal-title":"J. Nucl. Med. Off. Publ. Soc. Nucl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","article-title":"Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): A phase 3, randomised controlled trial","volume":"377","author":"Salles","year":"2011","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1200\/JCO.2012.45.0866","article-title":"R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi","volume":"31","author":"Federico","year":"2013","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1182\/blood-2014-11-537522","article-title":"FDG PET-CT in follicular lymphoma: A case-based evidence review","volume":"125","author":"Smith","year":"2015","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(15)00142-4","article-title":"A novel clinicogenetic prognostic score for follicular lymphoma","volume":"16","year":"2015","journal-title":"Lancet Oncol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/7\/2\/26\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:35:38Z","timestamp":1760207738000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/7\/2\/26"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["diagnostics7020026"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics7020026","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2017,5,12]]}}}